5-amino-1mq Injection

To clarify the application value of 5‑amino‑1mq injection in metabolic research, it is first necessary to understand its core mechanism-the inhibition of NNMT, which affects the nicotinamide metabolic pathway, regulates NAD+ biosynthesis, and ultimately maintains metabolic homeostasis.
NNMT is a metabolic enzyme widely distributed in the cytoplasm of human cells. Its core physiological function is to catalyze the methylation of nicotinamide (NAM, a key precursor for NAD+ synthesis) with S‑adenosylmethionine (SAM) to produce 1‑methylnicotinamide (1‑MNA). This reaction consumes large amounts of NAM and SAM simultaneously. Excessive NAM depletion directly reduces the substrate supply for NAD+ synthesis, leading to decreased intracellular NAD+ levels.

As a critical molecule in cellular energy metabolism and DNA repair, insufficient NAD+ directly triggers a series of metabolic abnormalities, including impaired mitochondrial function, reduced energy metabolism efficiency, and weakened DNA repair capacity. This is one of the core pathological mechanisms underlying obesity, diabetes, and other metabolic diseases.

As a derivative of methylquinolinium (MQ), 5-amino-1-methylquinolinium exhibits excellent cell membrane permeability and biocompatibility. Administered subcutaneously, its injectable form is rapidly absorbed and distributed to metabolically active tissues, where it specifically binds and inhibits NNMT catalytic activity without interfering with other enzymes in the nicotinamide pathway or NAD+ synthesis. This reduces potential confounding factors in research and provides a highly specific tool for metabolic studies.

Given its core advantage of selectively inhibiting NNMT and regulating NAD+ synthesis, 5-amino-1-methylquinolinium injection serves as a foundational tool for investigating the role of NNMT in energy metabolism and dissecting the molecular pathways of metabolic disorders.
In in vitro cell experiments, it is widely used to verify the relationship between NNMT activity and cellular energy metabolism. By treating metabolically active adipocytes and hepatocytes with 5-amino-1-methylquinolinium, researchers can precisely inhibit intracellular NNMT activity, monitor changes in the nicotinamide pathway and NAD+ levels, and analyze effects on energy metabolism.

Studies show that NNMT inhibition by 5-amino-1-methylquinolinium significantly reduces nicotinamide metabolism, increases NAM accumulation, improves NAD+ synthesis efficiency by over 30%, and markedly increases mitochondrial ATP production and cellular energy metabolism. These results directly confirm that excessive NNMT activation suppresses NAD+ synthesis and impairs energy metabolism, while NNMT inhibition effectively reverses this process, establishing NNMT as a negative regulator of energy metabolism.

Gradient‑dose 5-amino-1-methylquinolinium treatment further enables investigation of dose–response relationships between NNMT inhibition, NAD+ levels, and metabolic efficiency, improving mechanistic understanding and supporting target‑based research for metabolic diseases.
In animal model studies, the product is used to explore NNMT‑mediated regulation of whole‑body energy metabolism. Subcutaneous administration in normal and metabolically dysregulated mice significantly inhibits NNMT activity in metabolically active tissues (adipose, liver, muscle), increases systemic NAD+ levels, enhances mitochondrial function, and improves energy metabolism.

Treated mice show a 15%–20% increase in basal metabolic rate and elevated energy expenditure, with effects positively correlated with NNMT inhibition. Combined use of NNMT gene knockout and the product confirms causality:NNMT inhibition → enhanced NAD+ synthesis → improved energy metabolism
This provides a complete experimental evidence chain for NNMT's regulatory role. To date, it has become a core tool for studying NNMT in energy metabolism and advancing related research fields.

Glucose metabolism disorder is a hallmark of diabetes, insulin resistance, and related metabolic diseases. High NNMT expression is closely associated with glucose dysregulation: excessive NNMT activation disrupts nicotinamide metabolism, lowers NAD+ levels, impairs insulin signaling, reduces cellular glucose uptake and utilization, and promotes hyperglycemia and insulin resistance.
By precisely inhibiting NNMT, regulating the nicotinamide pathway, and maintaining NAD+ homeostasis, 5‑amino‑1mq injection plays an important role in research on glucose metabolism disorders and diabetes, particularly in insulin resistance mechanisms, glucose control validation, and diabetes complications.

In insulin resistance research, 5-amino-1-methylquinolinium injection is used to verify the relationship between NNMT and insulin resistance. In mouse models of insulin resistance, it significantly inhibits NNMT activity in liver and muscle, reduces NAM methylation, increases intracellular NAD+, activates the SIRT1 pathway, promotes phosphorylation of insulin receptor substrate 1 (IRS‑1), enhances insulin signaling, improves insulin sensitivity, and increases glucose uptake and utilization. This reduces fasting and postprandial blood glucose and reverses insulin resistance.

5-amino-1-methylquinolinium injection also upregulates GLUT4 (glucose transporter 4) expression, promoting glucose transport into adipose and muscle cells and reducing blood glucose accumulation. GLUT4 upregulation depends on stable NAD+ levels, further supporting the core mechanism of nicotinamide metabolism and NAD+ elevation.
In diabetes research, it is used to investigate the pathogenesis of type 2 diabetes and validate potential therapeutic effects. Type 2 diabetes is driven by insulin resistance and pancreatic β‑cell dysfunction. High NNMT exacerbates β‑cell oxidative stress and apoptosis, worsening disease progression.

Studies show that 5-amino-1-methylquinolinium injection inhibits NNMT, normalizes nicotinamide metabolism, elevates NAD+, reduces oxidative stress in β‑cells, suppresses apoptosis, preserves β‑cell function, and promotes insulin secretion, supporting long‑term glycemic control.
In mouse models of type 2 diabetes induced by a high‑fat diet and streptozotocin, 4 weeks of 5‑amino‑1mq injection reduced fasting blood glucose by 25%–30%, increased insulin secretion by over 20%, and significantly decreased β‑cell apoptosis.
Although research remains at the preclinical animal stage, the product has become an important tool for dissecting glucose metabolism disorders and diabetes and developing novel hypoglycemic agents, with its key advantage lying in nicotinamide pathway regulation and NAD+ stabilization.

The liver is a central metabolic organ responsible for lipid, glucose, and protein metabolism. Hepatic metabolic dysfunction contributes to fatty liver disease, cirrhosis, and other conditions. Metabolic dysfunction‑associated steatohepatitis (MASH, formerly non‑alcoholic steatohepatitis, NASH) is a major research focus, characterized by excessive hepatic fat accumulation, inflammation, and hepatocellular injury.
NNMT is highly expressed in the liver of obese and MASH patients. Its overactivation disrupts nicotinamide metabolism, reduces NAD+ levels, promotes hepatic lipid accumulation and lipotoxicity, and represents an important therapeutic target for hepatic metabolic disorders.

Through precise NNMT inhibition, nicotinamide regulation, and NAD+ elevation, the product is widely used in research on hepatic metabolic disorders and fatty liver disease, supporting mechanistic dissection and drug development.
In hepatic lipid metabolism studies, it is used to explore regulatory mechanisms and intervention strategies for hepatic steatosis. In mouse models of high‑fat diet‑induced liver steatosis, it significantly inhibits hepatic NNMT activity, reduces NAM methylation, increases NAD+ and SAM levels, enhances mitochondrial fatty acid oxidation, reduces hepatic triglyceride and lipid accumulation, lowers lipotoxicity markers (e.g., malondialdehyde, transaminases), improves hepatocellular injury, and reverses steatosis.

Treatment reduces hepatic triglyceride content by more than 30%, normalizes transaminase levels, and markedly alleviates hepatic steatosis. The product also downregulates lipogenic genes (e.g., FAS, SREBP‑1c), further improving hepatic lipid metabolism-again via nicotinamide regulation and NAD+ homeostasis.